The global pandemic was a watershed for the life science industry.
Businesses were forced not just to embrace new technologies and working methods, but to rethink existing operating models in order to deliver innovation at speed.
This has left a deep impact, accelerating changes that will shape the sector for years to come – from new clinical trial models and regulatory approval processes to digitalization and automation of processes.
Though hugely promising, these rapid advances can be difficult to adapt to in the short term.
They also raise ethical and legal questions around issues such as data privacy and health equity.
To find out what the industry is thinking about these trends, and a range of other opportunities, risks and challenges, we asked more than 600 industry leaders and decision-makers for their views.
Our respondents come from many different global regions and from a cross-section of businesses representing the life science ecosystem widely.
We also found some doubt about the effectiveness of risk management processes around clinical trials, which may be related to the rapid pace of change.